Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: billy d who wrote (958)	7/3/1998 2:39:00 PM
From: John R. Sashko	Respond to of 10280

The FDA approval letter put all the negative rumblings to rest. SEPR just needs to cross t's and dot i's on the package insert for final approval. I believe this drug will have a major impact. These respiratory conditions are common problems seen everyday. Beta agonists are not just used for asthma. COPD, bronchitis, and bronchiolitis are other uses. Levalbuterol clearly demonstrates advantages over available beta agonists. You would be amazed how excited asthma patients become when I inform them about levalbuterol. Sounds as if SEPR is gearing up for the 4th quarter release. I doubt that Levalbuterol will be added to insurance formularies quickly. Their bottom line is always cost. They seem to care little about therapeutic advantages of one medication over another. Hopefully, levalbuterol will be priced competitively and patient/physican demand will win out. John